<SEC-DOCUMENT>0000899243-22-004682.txt : 20220203
<SEC-HEADER>0000899243-22-004682.hdr.sgml : 20220203
<ACCEPTANCE-DATETIME>20220203183025
ACCESSION NUMBER:		0000899243-22-004682
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220201
FILED AS OF DATE:		20220203
DATE AS OF CHANGE:		20220203

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GRAINGER DAVID J
		CENTRAL INDEX KEY:			0001887115

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40445
		FILM NUMBER:		22590147

	MAIL ADDRESS:	
		STREET 1:		C/O CENTESSA PHARMACEUTICALS PLC
		STREET 2:		3RD FL., 1 ASHLEY RD, ALTRINCHAM
		CITY:			CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Centessa Pharmaceuticals plc
		CENTRAL INDEX KEY:			0001847903
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		44 7391 789784

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Centessa Pharmaceuticals Ltd
		DATE OF NAME CHANGE:	20210224
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-02-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001847903</issuerCik>
        <issuerName>Centessa Pharmaceuticals plc</issuerName>
        <issuerTradingSymbol>CNTA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001887115</rptOwnerCik>
            <rptOwnerName>GRAINGER DAVID J</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CENTESSA PHARMACEUTICALS PLC</rptOwnerStreet1>
            <rptOwnerStreet2>3RD FL., 1 ASHLEY RD, ALTRINCHAM</rptOwnerStreet2>
            <rptOwnerCity>CHESHIRE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>WA14 2DT</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Innovation Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Share Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>9.53</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2022-02-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>200000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-02-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>200000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>200000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">33,328 shares subject to such option shall vest and become exercisable on October 1,2022 and the remaining 166,672 shares subject to such option shall vest and become exercisable in 40 substantially equal installments on each monthly anniversary thereafter.</footnote>
        <footnote id="F2">The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Marella Thorell, attorney-in-fact</signatureName>
        <signatureDate>2022-02-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
